Literature DB >> 11444930

Beta-adrenergic receptors and calcium cycling proteins in non-failing, hypertrophied and failing human hearts: transition from hypertrophy to failure.

N R DiPaola1, W E Sweet, L B Stull, G S Francis, C Schomisch Moravec.   

Abstract

Left ventricular hypertrophy may lead to heart failure. The transition between hypertrophy and heart failure is, however, incompletely understood. On the cellular level, human heart failure is characterized by alterations in Ca(2+)-cycling proteins and beta-adrenergic receptor density, but the hypertrophied human heart remains largely under studied. In this investigation, 21 donor hearts which could not be used for transplantation were studied. Ten of these hearts came from organ donors with documented left ventricular hypertrophy and normal cardiac function. Eleven of the hearts were non-failing, obtained from individuals with no evidence of cardiac disease. Nine failing hearts from transplant recipients were also studied. beta-adrenergic receptor density was determined by radioligand binding. mRNA for atrial natriuretic factor, calsequestrin, sarcoplasmic reticulum Ca(2+)-ATPase, and phospholamban was measured by Northern blot. Actin, calsequestrin, sarcoplasmic reticulum Ca(2+)-ATPase, and phospholamban proteins were quantified by Western blot. In both hypertrophied and failing ventricles, mRNA for atrial natriuretic factor was expressed, as compared to no expression in non-failing hearts. In failing hearts, beta -adrenergic receptor density and both mRNA and protein levels of the Ca(2+)-ATPase were significantly decreased v non-failing hearts. By comparison, hypertrophied hearts showed a reduction in mRNA expression for both the Ca(2+)-ATPase and phospholamban with no change in the corresponding protein levels, and no change in beta-receptors. These data suggest that the previously demonstrated reduction in beta-adrenergic receptors and Ca(2+)-cycling proteins in the failing human heart may be features of the decompensated state, but are not found in human hearts with left ventricular hypertrophy and preserved systolic function. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11444930     DOI: 10.1006/jmcc.2001.1390

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  9 in total

1.  Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure.

Authors:  Miki Nonaka; Sachio Morimoto; Takashi Murayama; Nagomi Kurebayashi; Lei Li; Yuan-Yuan Wang; Masaki Arioka; Tatsuya Yoshihara; Fumi Takahashi-Yanaga; Toshiyuki Sasaguri
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

2.  S100A1 in human heart failure: lack of recovery following left ventricular assist device support.

Authors:  Mosi K Bennett; Wendy E Sweet; Sara Baicker-McKee; Elizabeth Looney; Kristen Karohl; Maria Mountis; W H Wilson Tang; Randall C Starling; Christine S Moravec
Journal:  Circ Heart Fail       Date:  2014-05-19       Impact factor: 8.790

3.  Expression of sarco (endo) plasmic reticulum calcium ATPase (SERCA) system in normal mouse cardiovascular tissues, heart failure and atherosclerosis.

Authors:  Larissa Lipskaia; Zela Keuylian; Karl Blirando; Nathalie Mougenot; Adeline Jacquet; Clotilde Rouxel; Haifa Sghairi; Ziane Elaib; Regis Blaise; Serge Adnot; Roger J Hajjar; Elie R Chemaly; Isabelle Limon; Regis Bobe
Journal:  Biochim Biophys Acta       Date:  2014-08-07

Review 4.  Computational models reduce complexity and accelerate insight into cardiac signaling networks.

Authors:  Jason H Yang; Jeffrey J Saucerman
Journal:  Circ Res       Date:  2011-01-07       Impact factor: 17.367

Review 5.  Experimental models of inherited cardiomyopathy and its therapeutics.

Authors:  Miki Nonaka; Sachio Morimoto
Journal:  World J Cardiol       Date:  2014-12-26

6.  Impaired β-adrenergic responsiveness accentuates dysfunctional excitation-contraction coupling in an ovine model of tachypacing-induced heart failure.

Authors:  Sarah J Briston; Jessica L Caldwell; Margaux A Horn; Jessica D Clarke; Mark A Richards; David J Greensmith; Helen K Graham; Mark C S Hall; David A Eisner; Katharine M Dibb; Andrew W Trafford
Journal:  J Physiol       Date:  2011-01-17       Impact factor: 5.182

Review 7.  What we know and do not know about sex and cardiac disease.

Authors:  John P Konhilas
Journal:  J Biomed Biotechnol       Date:  2010-04-22

Review 8.  Gene and cell therapy for heart failure.

Authors:  Ebo D de Muinck
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

9.  Ca²+-regulatory proteins in cardiomyocytes from the right ventricle in children with congenital heart disease.

Authors:  Yihe Wu; Wei Feng; Hao Zhang; Shoujun Li; De Wang; Xiangbin Pan; Shengshou Hu
Journal:  J Transl Med       Date:  2012-04-02       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.